BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 8626365)

  • 1. Therapeutic dose range of nefazodone in the treatment of major depression.
    Robinson DS; Marcus RN; Archibald DG; Hardy SA
    J Clin Psychiatry; 1996; 57 Suppl 2():6-9. PubMed ID: 8626365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, placebo-controlled trial of two dose ranges of nefazodone in the treatment of depressed outpatients.
    Mendels J; Reimherr F; Marcus RN; Roberts DL; Francis RJ; Anton SF
    J Clin Psychiatry; 1995; 56 Suppl 6():30-6. PubMed ID: 7649971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH
    J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile of nefazodone.
    Robinson DS; Roberts DL; Smith JM; Stringfellow JC; Kaplita SB; Seminara JA; Marcus RN
    J Clin Psychiatry; 1996; 57 Suppl 2():31-8. PubMed ID: 8626361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy.
    Bakish D; Hooper CL; Thornton MD; Wiens A; Miller CA; Thibaudeau CA
    Int Clin Psychopharmacol; 1997 Mar; 12(2):91-7. PubMed ID: 9219044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
    Zajecka JM
    J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant dosing and switching guidelines: focus on nefazodone.
    Zajecka J; McEnany GW; Lusk KM
    J Clin Psychiatry; 2002; 63 Suppl 1():42-7. PubMed ID: 11890564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nefazodone: single versus twice daily dose.
    Voris JC; Shaurette GN; Sebastian PS; Will-Wallace LA
    Pharmacotherapy; 1998; 18(2):379-80. PubMed ID: 9545158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nefazodone in the treatment of premenstrual syndrome: a preliminary study.
    Freeman EW; Rickels K; Sondheimer SJ; Denis A; Pfeifer S; Weil S
    J Clin Psychopharmacol; 1994 Jun; 14(3):180-6. PubMed ID: 8027414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.
    Argyropoulos SV; Hicks JA; Nash JR; Bell CJ; Rich AS; Nutt DJ; Wilson S
    J Sleep Res; 2009 Sep; 18(3):342-8. PubMed ID: 19549078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Placebo-controlled dose-ranging trial designs in phase II development of nefazodone.
    D'Amico MF; Roberts DL; Robinson DS; Schwiderski UE; Copp J
    Psychopharmacol Bull; 1990; 26(1):147-50. PubMed ID: 2196622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redefining antidepressant efficacy toward long-term recovery.
    Thase ME
    J Clin Psychiatry; 1999; 60 Suppl 6():15-9. PubMed ID: 10235120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nefazodone treatment of cocaine dependence with comorbid depressive symptoms.
    Ciraulo DA; Knapp C; Rotrosen J; Sarid-Segal O; Ciraulo AM; LoCastro J; Greenblatt DJ; Leiderman D
    Addiction; 2005 Mar; 100 Suppl 1():23-31. PubMed ID: 15730347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.